<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03816189</url>
  </required_header>
  <id_info>
    <org_study_id>2017_10</org_study_id>
    <secondary_id>2017-A02587-46</secondary_id>
    <nct_id>NCT03816189</nct_id>
  </id_info>
  <brief_title>Role of Eosinophil in Fibrogenesis of Systemic Sclerosis</brief_title>
  <acronym>EOFIB-SSC</acronym>
  <official_title>Role of Blood and Tissue Eosinophils in the Fibrogenesis of Systemic Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eosinophils are involved in tissue remodeling and fibrosis in many inflammatory diseases.&#xD;
      Systemic sclerosis (SSc) is an autoimmune disease with fibrotic skin and lung complications.&#xD;
      The profibrosing properties and data from the SSc literature suggest a possible role of the&#xD;
      eosinophils in the process of fibrogenesis of SSc.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      it will assess the activation state of blood eosinophils in SSc patients compared to healthy&#xD;
      controls (ECP production in vitro, surface activation markers, whole transcriptome array,&#xD;
      ..).&#xD;
&#xD;
      it will also study skin eosinophils and their recruitment (extracellular eosinophil granules,&#xD;
      eotaxins production in skin, ..)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 3, 2018</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of ECP concentrations in supernatants of eosinophils culture</measure>
    <time_frame>Baseline: one session</time_frame>
    <description>Eosinophils will be sorted, stimulated in vitro for 2 hours and ECP concentration will be assessed in supernatants</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of median fluorescence intensities of several surface markers on blood eosinophils, or comparison of percentages of positive cells among all eosinophils for a given marker (flow cytometry)</measure>
    <time_frame>Baseline: one session</time_frame>
    <description>MFI/% of CD69, HLA class II, CD9, CD11c, CD44, CCR3, CRTH2, IL-5R on blood eosinophils</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene expression profiles will be compared between SSc patients and healthy controls (whole transcriptome assay)</measure>
    <time_frame>Baseline: one session</time_frame>
    <description>Whole genome, transcriptomic approach (differentially expressed genes will be identified using a fold change cutoff)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In skin biopsies: density of eosinophils, extracellular ECP and MBP deposits (absent in healthy skin), and density of eotaxin-1-producing cells will be assessed in damaged skin and apparently healthy skin of SSc patients</measure>
    <time_frame>Baseline: one session</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">65</enrollment>
  <condition>Systemic Sclerosis</condition>
  <condition>Systemic Scleroderma</condition>
  <arm_group>
    <arm_group_label>Diffuse SSc</arm_group_label>
    <description>Recruitment of 20 patients with diffuse SSc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Limited SSc</arm_group_label>
    <description>Recruitment of 20 patients with limited SSc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy subjects</arm_group_label>
    <description>Recruitment of 20 healthy subjects (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Patients in each group will have a blood sample (9x7 mL) for eosinophils isolation, study of activation markers on whole blood and serum biomarkers testing</description>
    <arm_group_label>Diffuse SSc</arm_group_label>
    <arm_group_label>Healthy subjects</arm_group_label>
    <arm_group_label>Limited SSc</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Skin biopsies</intervention_name>
    <description>In patients who will accept, skin biopsies will be performed in damaged and apparently normal skin, excluding fingers, hands, feet and face (biopsies are facultative)</description>
    <arm_group_label>Diffuse SSc</arm_group_label>
    <arm_group_label>Limited SSc</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, Eosinophils, tissue&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The active line of the Internal Medicine department (&gt; 400 sclerodermic patients)&#xD;
        guarantees the recruitment of 20 diffuse forms and 20 limited forms&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For SSc patients:&#xD;
&#xD;
          -  Meeting the 2013 ACR-EULAR criteria for diffuse SSc (n = 20) and limited SSc (n = 20)&#xD;
&#xD;
          -  Having signed the informed consent&#xD;
&#xD;
          -  Eosinophils ≥ 0.1 G / L on the last blood test (&lt;3 months)&#xD;
&#xD;
        For healthy subjects:&#xD;
&#xD;
          -  Without chronic pathology requiring long-term treatment&#xD;
&#xD;
          -  Eosinophils between 0.1 and 0.4 G / L on recent blood test (&lt;3 months)&#xD;
&#xD;
        Exclusion Criteria for patients and controls:&#xD;
&#xD;
          -  Patient with an infection, state of emergency or progressive neoplastic pathology&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  History of atopy (allergic asthma, atopic eczema, allergic rhinitis, allergic&#xD;
             conjunctivitis)&#xD;
&#xD;
          -  Allergy to local anesthetics (for scleroderma patients only)&#xD;
&#xD;
          -  Taking into account a minimum weight of 50 kg and in the absence of cardiorespiratory&#xD;
             effects of scleroderma, only patients with at least 10 g of hemoglobin will be&#xD;
             included&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>66 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillaume Lefevre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Claude Huriez, CHU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2019</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Eosinophil</keyword>
  <keyword>Fibrosis</keyword>
  <keyword>Systemic Scleroderma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

